For an adult male with symptomatic benign prostatic hyperplasia, how do finasteride and dutasteride compare in efficacy, prostate volume reduction, side effects, and cost?

Finasteride vs Dutasteride for BPH

For symptomatic BPH, both finasteride and dutasteride are effective, but dutasteride achieves superior prostate volume reduction and slightly better symptom improvement, while both drugs have comparable safety profiles and sexual side effects. 1

Efficacy Comparison

Symptom Improvement

Both medications effectively reduce LUTS severity, but dutasteride demonstrates a modest advantage:

• Dutasteride produces greater IPSS reduction (-6.8 points) compared to finasteride (-5.9 points), with a statistically significant difference of approximately 0.9-1.8 points 2, 3
• The only head-to-head trial (EPICS study) found no significant differences in symptom scores at 12 months, though this may reflect insufficient follow-up duration 1
• Both agents show sustained symptom improvement maintained for 4-10 years 4

Prostate Volume Reduction

Dutasteride is definitively superior for prostate volume reduction:

• Dutasteride reduces prostate volume by 26-27% at 24 months 5, 2
• Finasteride reduces prostate volume by 18% at 24 months 2
• The difference (-8% greater reduction with dutasteride) is statistically significant (p=0.008) 2
• This reflects dutasteride's dual inhibition of both type 1 and type 2 5-alpha-reductase (95% DHT reduction) versus finasteride's selective type 2 inhibition (70% DHT reduction) 1

Urodynamic Outcomes

• Dutasteride shows slightly better Qmax improvement (0.32 mL/sec greater than finasteride, p=0.04) 6
• Both drugs improve maximum flow rates by 1.6-2.4 mL/sec from baseline 5
• Post-void residual volumes show no significant difference between agents 3

Disease Progression Prevention

Both medications reduce risk of acute urinary retention and BPH-related surgery:

• Dutasteride reduces AUR risk by 57% and surgical risk by 48% versus placebo 5
• Real-world data suggests dutasteride may have an 18% lower risk of BPH-related surgery compared to finasteride (HR 0.82, p=0.0025) 7
• Minimum prostate volume >30cc or PSA >1.5 ng/mL is necessary for reliable 5-ARI response 1

Safety and Side Effects

Sexual Function

Both drugs have equivalent sexual side effects:

• Erectile dysfunction, decreased libido, and ejaculatory dysfunction occur with similar frequency 2, 6, 3
• IIEF-5 score changes are comparable: dutasteride (-0.9 points) vs finasteride (-0.7 points), p=0.51 2
• Post-finasteride syndrome remains controversial with unclear evidence quality 1

Other Adverse Effects

• Gynecomastia can occur with both agents 1
• Overall adverse event rates show no significant difference (p=0.66-0.72) 6, 3
• Renal function remains stable with both medications 2

PSA Effects

• Dutasteride reduces PSA by 44% versus finasteride's 33% reduction (p=0.014) 2
• After 1 year of therapy, double the measured PSA value to screen for prostate cancer 1
• Free/total PSA ratio remains constant with both drugs 1

Clinical Decision Algorithm

Choose dutasteride when:

• Prostate volume is significantly enlarged (>50cc)
• Maximum symptom reduction is the priority
• Patient can afford the higher cost

Choose finasteride when:

• Cost is a primary concern (finasteride is less expensive)
• Prostate volume is moderately enlarged (30-50cc)
• Patient preference after discussing equivalent sexual side effects

For both medications:

• Confirm prostate volume >30cc or PSA >1.5 ng/mL before initiating 1
• Counsel patients on 6-12 month onset of action (slower than alpha-blockers) 1
• Consider combination therapy with tamsulosin for faster symptom relief 4, 5
• Monitor PSA and double the value when screening for prostate cancer 1

Cost Considerations

Real-world budget impact analysis shows dutasteride produces a net savings of approximately €3,933 per 1,000 patients treated for 1 year when accounting for reduced hospitalization rates 7. However, medication acquisition costs typically favor finasteride in most healthcare systems.

Common Pitfalls

• Don't use 5-ARIs in prostates <30cc - insufficient response 1
• Don't forget to adjust PSA screening - failure to double PSA values leads to missed prostate cancers 1
• Don't expect rapid symptom relief - onset requires 6-12 months, unlike alpha-blockers 1
• Don't assume dutasteride prevents more prostate cancers - recent pooled analysis of 15 databases found no significant difference (HR 0.87, p=0.310) 8